Calton & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-6,716
Closed -$362K 446
2025
Q4
$362K Buy
+6,716
New +$323K 0.05% 289
2024
Q4
Sell
-15,503
Closed -$802K 199
2024
Q3
$802K Buy
15,503
+5,711
+58% +$268K 0.31% 77
2024
Q2
$407K Sell
9,792
-994
-9% -$44.5K 0.2% 108
2024
Q1
$585K Buy
+10,786
New +$549K 0.29% 83
2023
Q1
Sell
-2,865
Closed -$206K 243
2022
Q4
$206K Buy
+2,865
New +$216K 0.08% 257
2022
Q1
Sell
-4,145
Closed -$258K 361
2021
Q4
$258K Sell
4,145
-1,882
-31% -$110K 0.07% 298
2021
Q3
$356K Sell
6,027
-551
-8% -$36.3K 0.08% 253
2021
Q2
$439K Buy
6,578
+96
+1% +$6.26K 0.08% 218
2021
Q1
$409K Sell
6,482
-1,989
-23% -$124K 0.08% 223
2020
Q4
$525K Sell
8,471
-1,743
-17% -$107K 0.09% 174
2020
Q3
$616K Sell
10,214
-1,249
-11% -$75.2K 0.13% 136
2020
Q2
$674K Buy
11,463
+756
+7% +$45.2K 0.15% 114
2020
Q1
$597K Sell
10,707
-2,225
-17% -$136K 0.15% 123
2019
Q4
$830K Buy
12,932
+4,923
+61% +$282K 0.17% 116
2019
Q3
$406K Sell
8,009
-550
-6% -$25.8K 0.09% 184
2019
Q2
$388K Buy
8,559
+68
+0.8% +$3.17K 0.11% 158
2019
Q1
$405K Sell
8,491
-1,180
-12% -$58.8K 0.12% 152
2018
Q4
$503K Buy
9,671
+1,224
+14% +$65.8K 0.19% 109
2018
Q3
$524K Sell
8,447
-2,733
-24% -$162K 0.15% 114
2018
Q2
$673K Sell
11,180
-6,331
-36% -$342K 0.2% 88
2018
Q1
$1.11M Buy
17,511
+967
+6% +$62.2K 0.32% 62
2017
Q4
$1.05M Buy
+16,544
New +$1.03M 0.26% 67

Other funds holding BMY

Calton & Associates's BMY Position: Q1 2026 in Review

Calton & Associates sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 6,716 shares — an estimated $362K sold.

Calton & Associates first reported a position in BMY in Q4 2017 and held it in 22 quarters. The position peaked at $1.11M in Q1 2018. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Calton & Associates reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
  • Calton & Associates sold 6,716 Bristol-Myers Squibb shares in Q1 2026, an estimated $362K.
  • Calton & Associates first reported a position in Bristol-Myers Squibb in Q4 2017 and held it in 22 quarters.
  • Calton & Associates's Bristol-Myers Squibb position peaked at $1.11M in Q1 2018.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Calton & Associates's 13F filing for Q1 2026, filed 13 May 2026.